Merck & Company Inc (MRK)vsInsulet Corporation (PODD)
MRK
Merck & Company Inc
$143.93
-0.54%
HEALTHCARE · Cap: $355.10B
PODD
Insulet Corporation
$131.96
-2.02%
HEALTHCARE · Cap: $9.87B
Smart Verdict
WallStSmart Research — data-driven comparison
Merck & Company Inc generates 2080% more annual revenue ($66.57B vs $3.05B). PODD leads profitability with a 12.3% profit margin vs 4.8%. PODD appears more attractively valued with a PEG of 1.16. PODD earns a higher WallStSmart Score of 71/100 (B).
MRK
Hold36
out of 100
Grade: F
PODD
Strong Buy71
out of 100
Grade: B
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
-73.7%
Fair Value
$82.84
Current Price
$143.93
$61.09 premium
Intrinsic value data unavailable for PODD.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Mega-cap, among the largest globally
Generating 4.5B in free cash flow
Earnings expanding 328.6% YoY
Every $100 of equity generates 23 in profit
Revenue surging 23.5% year-over-year
Areas to Watch
Trading at 8.5x book value
ROE of 7.6% — below average capital efficiency
4.8% margin — thin
Elevated debt levels
Moderate valuation
Comparative Analysis Report
WallStSmart ResearchBull Case : MRK
The strongest argument for MRK centers on Market Cap, Free Cash Flow.
Bull Case : PODD
The strongest argument for PODD centers on EPS Growth, Return on Equity, Revenue Growth. Revenue growth of 23.5% demonstrates continued momentum. PEG of 1.16 suggests the stock is reasonably priced for its growth.
Bear Case : MRK
The primary concerns for MRK are Price/Book, Return on Equity, Profit Margin. A P/E of 116.1x leaves little room for execution misses. Thin 4.8% margins leave little buffer for downturns.
Bear Case : PODD
The primary concerns for PODD are P/E Ratio.
Key Dynamics to Monitor
MRK profiles as a value stock while PODD is a growth play — different risk/reward profiles.
PODD carries more volatility with a beta of 1.08 — expect wider price swings.
PODD is growing revenue faster at 23.5% — sustainability is the question.
MRK generates stronger free cash flow (4.5B), providing more financial flexibility.
Bottom Line
PODD scores higher overall (71/100 vs 36/100) and 23.5% revenue growth. Both earn "Strong Buy" and "Hold" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
Merck & Company Inc
HEALTHCARE · DRUG MANUFACTURERS - GENERAL · USA
Merck & Co. is an American multinational pharmaceutical company headquartered in Kenilworth, New Jersey. It is named after the Merck family, which set up Merck Group in Germany in 1668.
Visit Website →Insulet Corporation
HEALTHCARE · MEDICAL DEVICES · USA
Insulet Corporation develops, manufactures, and sells insulin delivery systems for people with insulin-dependent diabetes. The company is headquartered in Acton, Massachusetts.
Compare with Other DRUG MANUFACTURERS - GENERAL Stocks
Want to dig deeper into these stocks?